Publications

  1. Wagner IV, Stewart MW, Dorairaj SK. Updates on the Diagnosis and Management of Glaucoma. Mayo Clin Proc Innov Qual Outcomes. 2022 Dec; 6 (6):618-635 Epub 2022 Nov 16
    View PubMed
  2. Stewart MW, Garg S, Newman EM, Jeffords E, Konopinska J, Jackson S, Sikorski BL, Rawner ES. SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2022 Jun 1; 42 (6):1038-1046
    View PubMed
  3. Wagner IV, Dorairaj SK, Miller DD, Ten Hulzen RD, Stewart MW. Delayed intracapsular hematoma after use of iris retractor hooks Journal of Cataract and Refractive Surgery Online Case Report. 2022; 10(2):00080.
  4. Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW. IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review. Retina. 2022 Apr 1; 42 (4):589-606
    View PubMed
  5. Kedarisetti KC, Narayanan R, Stewart MW, Reddy Gurram N, Khanani AM. Macular Telangiectasia Type 2: A Comprehensive Review. Clin Ophthalmol. 2022; 16:3297-3309 Epub 2022 Oct 10
    View PubMed
  6. Chakraborty D, Stewart MW, Sheth JU, Sinha TK, Boral S, Das A, Mondal S, Mukherjee A. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. Ophthalmol Ther. 2021 Jun; 10 (2):337-348 Epub 2021 Apr 17
    View PubMed
  7. Eissing T, Stewart MW, Qian CX, Rittenhouse KD. Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes. Transl Vis Sci Technol. 2021 Apr 1; 10 (4):9
    View PubMed
  8. Sheth JU, Stewart MW, Khatri M, Gupta SR, Chawla S, Rajendran A, Narayanan R. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey. Indian J Ophthalmol. 2021 Feb; 69 (2):352-356
    View PubMed
  9. Grzybowski A, Brona P, Zeman L, Stewart MW. Commonly used intracameral antibiotics for endophthalmitis prophylaxis: A literature review. Surv Ophthalmol. 2021 Jan - Feb; 66 (1):98-108 Epub 2020 Apr 25
    View PubMed
  10. Farford BA, Ahuja AS, Stewart MW, Naessens JM, Keith JJ. Screening for Diabetic Retinopathy with a Nonmydriatic Ultra-Wide-Field Retina Camera by Family Medicine Physicians. J Am Board Fam Med. 2021 Jan-Feb; 34 (1):231-237
    View PubMed
  11. Chaves AC, Grosinger AJ, Ten Hulzen RD, Stewart MW, Dorairaj SK. Endophthalmitis following combined cataract extraction and placement of an iStent trabecular bypass device. Am J Ophthalmol Case Rep. 2020 Dec; 20:100830 Epub 2020 Aug 14
    View PubMed
  12. Mansour AM, Stewart MW, Farah ME, Mansour HA, Chhablani J. Ziv-aflibercept: A cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor. Acta Ophthalmol. 2020 Aug; 98 (5):e540-e548 Epub 2019 Dec 20
    View PubMed
  13. Stewart MW, Hasan SA, Collins C, Stanko C, Summer J, Brazis PW, Tawk R, Freeman WD. Can Baseline Computed Tomography Scans Be Used to Identify Patients at High Risk of Vision Loss due to Terson Syndrome? Am J Ophthalmol. 2020 Mar; 211:217-228 Epub 2019 Sept 25
    View PubMed
  14. Mansour A, Stewart MW, Charbaji AR, El Jawhari KM, El Zein L, Mansour MA, Saade JS. Perceived Surgeon Stress During No-Sedation Topical Phacoemulsification. Clin Ophthalmol. 2020; 14:2373-2381 Epub 2020 Aug 18
    View PubMed
  15. Miller DD, Stewart MW, Gagne JJ, Wagner AL, Lee AY. Differences in characteristics of Medicare patients treated by ophthalmologists and optometrists. PLoS One. 2020; 15 (9):e0227783 Epub 2020 Sept 14
    View PubMed
  16. Taylor K, Stewart MW. Letter to the Editor Regarding the "Effectiveness of 190 microg Fluocinolone Acetonide and 700 microg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The Constant Analysis" Article [Letter]. Clin Ophthalmol. 2020; 14:3811-3812 Epub 2020 Nov 05
    View PubMed
  17. Mansour A, Stewart MW, Shields CL, Hamam R, Abdul Fattah M, Sheheitli H, Mehanna CJ, Yassine S, Chahine H, Keaik M, Maalouf F, Jaroudi M. Extensive circumferential partial-thickness sclerectomy in eyes with extreme nanophthalmos and spontaneous uveal effusion. Br J Ophthalmol. 2019 Dec; 103 (12):1862-1867 Epub 2019 Mar 15
    View PubMed
  18. Mansour AM, Stewart MW, Yassine SW, Mehanna CZ, Casella AMB, Hamam RN, Chhablani J, Lima LH, Shinojima A, Kaneko H, Younis MH, Shahin HK, Jalali S, Kucukerdonmez C, Saatci AO, Chakurkar R, Shields CL. Unmeasurable small size superficial and deep foveal avascular zone in nanophthalmos: the Collaborative Nanophthalmos OCTA Study. Br J Ophthalmol. 2019 Aug; 103 (8):1173-1178 Epub 2018 Oct 15
    View PubMed
  19. Singh SR, Stewart MW, Chattannavar G, Ashraf M, Souka A, ElDardeery M, Wadhwa N, Sarvaiya C, Mansour AM, Marashi A, Ramchandani S, Braimah IZ, Jabbarpoor Bonyadi MH, Ramezani A, Soheilian M, de Oliveira Dias JR, de Andrade GC, Maia A, Rodrigues EB, Farah ME, Banker A, Chhablani J, Ziv-aflibercept Study Group. Safety of 5914 intravitreal ziv-aflibercept injections. Br J Ophthalmol. 2019 Jun; 103 (6):805-810 Epub 2018 Aug 11
    View PubMed
  20. Heckman AJ, Alsaad AA, Stewart MW, Maniaci MJ. Acute Unilateral Vision Loss Due to Optic Neuropathy in a Patient with Systemic Lupus Erythematosus. Am J Case Rep. 2019 Jan 23; 20:97-100
    View PubMed
  21. Miller DD, Hasan SA, Simmons NL, Stewart MW. Recurrent corneal erosion: a comprehensive review. Clin Ophthalmol. 2019; 13:325-335 Epub 2019 Feb 11
    View PubMed
  22. Stewart MW. Macular degeneration a to z: Learn the most important terms of this disease Ophthalmology Times. 2019; Spring:1-4, 7, 10
  23. George NK, Stewart MW. The Routine Use of Intracameral Antibiotics to Prevent Endophthalmitis After Cataract Surgery: How Good is the Evidence? Ophthalmol Ther. 2018 Dec; 7 (2):233-245 Epub 2018 July 05
    View PubMed
  24. Agarwal A, Grewal DS, Jaffe GJ, Stewart MW, Srivastava S, Gupta V. Current role of optical coherence tomography angiography: Expert panel discussion. Indian J Ophthalmol. 2018 Dec; 66 (12):1696-1699
    View PubMed
  25. Browning DJ, Stewart MW, Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol. 2018 Dec; 66 (12):1736-1750
    View PubMed
  26. Stewart MW, Browning DJ, Landers MB. Current management of diabetic tractional retinal detachments. Indian J Ophthalmol. 2018 Dec; 66 (12):1751-1762
    View PubMed
  27. Narayanan R, Stewart MW, Chhablani J, Panchal B, Pappuru RR, Das T, Jalali S, Ali MH. Baseline morphological characteristics as predictors of final visual acuity in patients with branch retinal vein occlusions: MARVEL report no. 3. Indian J Ophthalmol. 2018 Sep; 66 (9):1291-1294
    View PubMed
  28. Michalewska Z, Stewart MW, Landers MB 3rd, Bednarski M, Adelman RA, Nawrocki J. Vitrectomy in the management of diabetic macular edema in treatment-naive patients. Can J Ophthalmol. 2018 Aug; 53 (4):402-407 Epub 2017 Dec 23
    View PubMed
  29. Gold KG, Scofield S, Isaacson SR, Stewart MW, Kazim M. Orbital Radiotherapy Combined With Corticosteroid Treatment for Thyroid Eye Disease-Compressive Optic Neuropathy. Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr; 34 (2):172-177
    View PubMed
  30. Stewart MW. Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities. Pharmaceutics. 2018 Jan 27; 10 (1)
    View PubMed
  31. Chhablani J, Stewart M, Paulose R, Gallego-Pinazo R, Dolz-Marco R. Clinical Characteristics and Treatment Outcomes of Recurrent Central Retinal Vein Occlusions. Semin Ophthalmol. 2018; 33 (2):191-197 Epub 2016 Sept 09
    View PubMed
  32. Stewart MW. The study of intravitreal drug pharmacokinetics: does it matter? and if so, how? Expert Opin Drug Metab Toxicol 2018 Jan; 14 (1):5-7 Epub 2017 Dec 12
    View PubMed
  33. Stewart MW. Technician plays key role in ophthalmic exam: Some components of the ophthalmic exam are performed by technicians, requiring adequate knowledge of eye to diagnose appropriately Ophthalmology Times. 2018; (Fall, itech):1, 3-4
  34. Stewart MW. Technician plays key role in ophthalmic exam Ophthalmology Times. 2018; 43 (17):1-4
  35. Aptel F, Colin C, Kaderli S, Deloche C, Bron AM, Stewart MW, Chiquet C, OSIRIS group. Management of postoperative inflammation after cataract and complex ocular surgeries: a systematic review and Delphi survey. Br J Ophthalmol. 2017 Nov; 101 (11):1-10 Epub 2017 Aug 03
    View PubMed
  36. Singh SR, Dogra A, Stewart M, Das T, Chhablani J. Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact. Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec; 6 (6):561-568 Epub 2017 Oct 03
    View PubMed
  37. Stewart MW. Ophthalmologic Disease in HIV Infection: Recent Changes in Pathophysiology and Treatment. Curr Infect Dis Rep. 2017 Oct 19; 19 (12):47
    View PubMed
  38. Stewart MW. Future Treatments of Diabetic Retinopathy: Pharmacotherapeutic Products Under Development European Medical Journal Diabetes .2017;93-103.
  39. Chhablani J, Dedhia CJ, Peguda HK, Stewart M. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT. Retina. 2017 Oct; 37 (10):1859-1865
    View PubMed
  40. Braimah IZ, Stewart M, Videkar C, Dedhia CJ, Chhablani J, 'Ziv-aflibercept study group'. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Br J Ophthalmol. 2017 Sep; 101 (9):1201-1205 Epub 2017 Jan 24
    View PubMed
  41. Gutierrez-Aguirre KI, Stewart MW, Sluzevich JC. SCLEROMYXEDEMA WITH RETINAL VASCULITIS AND MACULAR EDEMA. Retin Cases Brief Rep. 2017 Fall; 11 (4):319-322
    View PubMed
  42. Stewart MW. A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmol Ther. 2017 Jun; 6: (1)33-47.
    View PubMed
  43. Yogi R, Stewart M, Chhablani J. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT. Retin Cases Brief Rep. 2017 Spring; 11 (2):111-113
    View PubMed
  44. Krambeer C, Singer M, Jansen M, Ober M, Stewart M, Shah G, et al. Retina Specialists: How we Think. Austin Ophthalmol. 2017; 2(1): 1008..2017;
  45. Smithwick E, Stewart MW. Designed Ankyrin Repeat Proteins: A Look at their Evolving Use in Medicine with a Focus on the Treatment of Chorioretinal Vascular Disorders. Antiinflamm Antiallergy Agents Med Chem. 2017; 16 (1):33-45
    View PubMed
  46. Stewart MW. Intravitreal anti-VEGF drug use in industrialized nations: why are newly introduced medications causing us to inject more and not less? Curr Med Res Opin 2016 Dec; 32 (12):1951-1953 Epub 2016 Oct 08
    View PubMed
  47. Stewart MW. Treatment strategies for chorioretinal vascular diseases: advantages and disadvantages of individualized therapy. EMJ Diabet 2016;4(1):91-98.2016;
  48. Stewart MW, Narayanan R, Gupta V, Rosenfeld PJ, Martin DF, Chakravarthy U. Counterfeit Avastin in India: Punish the Criminals, Not the Patients. Am J Ophthalmol. 2016 Oct; 170:228-231.
    View PubMed
  49. Stewart MW, Flynn HW Jr, Schwartz SG, Scott IU. Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects. Expert Opin Drug Deliv. 2016 Sep; 13 (9):1277-87 Epub 2016 June 22
    View PubMed
  50. Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes. 2016 Aug 25; 7 (16):333-41
    View PubMed
  51. Chhablani J, Narayanan R, Mathai A, Yogi R, Stewart M. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT. Retina. 2016 Jun; 36 (6):1126-31
    View PubMed
  52. Stewart MW, Landers MB 3rd, Browning DJ, Murata T, Ohji M, Nawrocki J, Chhablani JK. Correspondence. Retina 2016 Mar; 36 (3):e22-3
    View PubMed
  53. Paulose R, Chhablani J, Dedhia CJ, Stewart MW, Mansour AM. Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion. Clin Ophthalmol. 2016; 10:1853-1858 Epub 2016 Sept 22
    View PubMed
  54. Schwartz SG, Scott IU, Stewart MW, Flynn HW Jr. Update on corticosteroids for diabetic macular edema. Clin Ophthalmol. 2016; 10:1723-30 Epub 2016 Sept 08
    View PubMed
  55. Syed Z, Stewart MW. Age-dependent vitreous separation from the macula in a clinic population Clinical Ophthalmology. 2016; 10:1237-43.
  56. Narayanan R, Panchal B, Stewart MW, Das T, Chhablani J, Jalali S, Hasnat Ali M. Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2. Clin Ophthalmol. 2016; 10:1023-9 Epub 2016 June 02
    View PubMed
  57. Browning DJ, Lee C, Stewart MW, Landers MB 3rd. Vitrectomy for center-involved diabetic macular edema. Clin Ophthalmol. 2016; 10:735-42 Epub 2016 Apr 26
    View PubMed
  58. Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY. Retina. 2015 Aug; 35: (8)1604-14.
    View PubMed
  59. Stewart MW. Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing? J Clin Med. 2015 May 21; 4 (5):1079-101
    View PubMed
  60. Stewart MW. Anti-Vascular Endothelial Growth Factor Therapy for Chorioretinal Vascular Diseases: An Update. Current Medical Literature Ophthalmology.2015;25:(3):61-71.
  61. Stewart MW. Case Presentation: diabetic macular edema unresponsive to bevacizumab. Intravitreal Interventions. 2015; 4(2).
  62. Stewart MW. The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes. 2015; 8:473-482.
  63. Stewart MW, Pulido J, Nicholson B, Freund KB. Unusual vascular lesion unresponsive to bevacizumab. Intravitreal Interventions. 2015; 4(1).
  64. Stewart MW. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep. 2014 Aug; 14 (8):510
    View PubMed
  65. Moore SA, Rabinstein AA, Stewart MW, David Freeman W. Recognizing the signs and symptoms of aneurysmal subarachnoid hemorrhage. Expert Rev Neurother. 2014 Jul; 14(7):757-68.
    View PubMed
  66. Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014 Mar; 7(2):167-80. Epub 2014 Feb 03.
    View PubMed
  67. Stewart MW. Review of the latest treatments for retinal vein occlusions: Emphasis on pharmacologic therapy. Expert Rev. Ophthalmol. 2014; 9(5):361-74.
  68. Stewart MW. Sudden vision loss with optic disc swelling and retinal hemorrhages. Intravitreal Interventions 20. 2014; 3(3):17.
  69. Vanner EA, Stewart MW. Meta-analysis comparing same-day versus delayed vitrectomy clinical outcomes for intravitreal retained lens fragments after age-related cataract surgery. Clin Ophthalmol. 2014; 8:2261-76 Epub 2014 Nov 18
    View PubMed
  70. Maturi RK, Chen V, Raghinaru D, Bleau L, Stewart MW. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. Clin Ophthalmol. 2014; 8:1057-64 Epub 2014 June 03
    View PubMed
  71. Schwartz SG, Scott IU, Flynn HW Jr, Stewart MW. Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv. 2014 Jan; 11(1):61-8. Epub 2013 Nov 13
    View PubMed
  72. Stewart MW. Clinically relevant pharmacology of anti-VEGF agents. Intravitreal Interventions. 2014; 3(1):1, 4-6.
  73. Kaiser PK, Brown DM, Kitchens JW, MacCumber MW, Singh RP, Stewart MW. The impact of anti-VEGF treatments on naïve AMD patients. How to choose an agent Part 1 Retinal Physician. 2014; June Suppl:1-17.
  74. Smith CD, Spackman T, Brommer K, Stewart MW, Vizzini M, Frye J, Rupp WC. Re-engineering the operating room using variability methodology to improve health care value. J Am Coll Surg. 2013 Apr; 216(4):559-68; discussion 568-70.
    View PubMed
  75. Stewart MW. Herpetic (non-cytomegalovirus) retinal infections in patients with the acquired immunodeficiency syndrome. Curr HIV Res. 2013 Apr; 11(3):210-9.
    View PubMed
  76. Stewart MW. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Rev Clin Pharmacol. 2013 Mar; 6 (2):103-13
    View PubMed
  77. Stewart MW. 1-year results of intravitreal aflibercept treatment for macular edema due to central retinal vein occlusion. Expert Rev. Ophthalmol. 2013; 8(3):241-4.
  78. Stewart MW. One-year results of intravitreal ranibizumab 0.5 mg vs 20 mg for the treatment of exudative age-related macular degeneration. Expert Rev Ophthalmol. 2013; 8(4):341-345.
  79. Stewart MW. Aflibercept Ophthalmic Solution: Drug development and clinical uses. Clinical Investigation. 2013; 3(11):1045-56.
  80. Stewart MW. Aflibercept in the treatment of wet macular degeneration. J Signs Symptoms. 2013; 2(4):203-212.
  81. Stewart MW. PDGF: ophthalmology's next great target. Exp Rev Ophthalmol. 2013; 8(6):527-537.
  82. Stewart MW. Aflibercept as a treatment for age-related macular degeneration. US Ophthalmic Reviews. 2013; 6(1):58-63.
  83. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol. 2013; 7:1257-67. Epub 2013 Jun 24.
    View PubMed
  84. Stewart MW. Review of aflibercept for the treatment of neovascular age-related macular degeneration. Clinical Medicine Insights: Therapeutics. 2013; 5:81-93.
  85. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Ocular Times. 2013.
  86. Stewart ML. Topical azithromycin or ofloxacin for endophthalmitis. Clin Ophthalmol. 2013; 7:35-6 Epub 2012 Dec 31
    View PubMed
  87. Forlenza GP, Stewart MW. Diabetic retinopathy in children. Pediatr Endocrinol Rev. 2012 Dec-2013 Jan; 10(2):217-26.
    View PubMed
  88. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012 Aug; 154(2):222-6.
    View PubMed
  89. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012 Aug; 12 (4):364-75
    View PubMed
  90. Stewart MW. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev. 2012 Jul 1; 8 (4):237-46
    View PubMed
  91. Butendieck RR, Parikh K, Stewart M, Davidge-Pitts C, Abril A. Systemic lupus erythematosus-associated retinal vasculitis. J Rheumatol. 2012 May; 39(5):1095-6.
    View PubMed
  92. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012 Mar; 32 (3):434-57
    View PubMed
  93. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn't blind people, people blind people. Am J Ophthalmol. 2012 Feb; 153(2):196-203.e1.
    View PubMed
  94. Stewart MW. Human immunodeficiency virus and its effects on the visual system. Infect Dis Rep. 2012 Jan 2; 4 (1):e25 Epub 2012 Mar 08
    View PubMed
  95. Stewart MW. Unilateral vision loss following contralateral eye treatment. Intravitreal Interventions. 2012; 1(2):13.
  96. Stewart MW. Early experience using aflibercept in the treatment of wet macular degeneration. Intravitreal Interventions. 2012; 1(4):1-11.
  97. Stewart MW. New anti-VEGF antibody therapies in Ophthalmology. Curr Med Literature - Ophthalmology. 2012; 22(4):105-113.
  98. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012 Jan; 87 (1):77-88
    View PubMed
  99. Stewart MW. Vascular endothelial growth factor (VEGF) biochemistry and development of inhibitory drugs. Current Drug Therapy. 2012; 7(2):80-9.
  100. Stewart MW. Vascular endothelial growth factor inhibitor use in ophthalmology: The revolution continues. Current Drug Therapy. 2012; 7(2):77-9.
  101. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012; 6:1175-86 Epub 2012 July 26
    View PubMed
  102. Stewart MW. Pharmacokinetics of intravitreal anti-VEGF agents: practical clinical implications. Intervitreal Interventions. 2012; 1(1):1-4.
  103. Vanner EA, Stewart MW, Liesegang TJ, Bendel RE, Bolling JP, Hasan SA. A retrospective cohort study of clinical outcomes for intravitreal crystalline retained lens fragments after age-related cataract surgery: a comparison of same-day versus delayed vitrectomy. Clin Ophthalmol. 2012; 6:1135-48. Epub 2012 Jul 18.
    View PubMed
  104. Stewart MW. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets. 2011 Dec; 10 (6):497-508
    View PubMed
  105. Davis J, Olsen TW, Stewart M, Sternberg P Jr. How the comparison of age-related macular degeneration treatments trial results will impact clinical care. Am J Ophthalmol. 2011 Oct; 152: (4)509-14.
    View PubMed
  106. Vanner EA, Stewart MW. Vitrectomy timing for retained lens fragments after surgery for age-related cataracts: a systematic review and meta-analysis. Am J Ophthalmol. 2011 Sep; 152 (3):345-357.e3 Epub 2011 June 17
    View PubMed
  107. Stewart MW, Vavra MW, Whaley NR. Fundus findings in a patient with [alpha]-methylacyl-CoA racemase deficiency. Retinal Cases and Brief Reports. 2011; 5(3):262-266.
  108. Stewart MW. What are the half-lives of ranibizumab, aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Reports. 2011; 1(1):12-14.
  109. Stewart MW. Impact of HIV on vision. Northeast Florida Medicine. 2011; 62(2):3-8.
  110. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol. 2010; 4:285-99. Epub 2010 Apr 26.
    View PubMed
  111. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008 May; 92 (5):667-8 Epub 2008 Mar 20
    View PubMed
  112. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina. 2007 Nov-Dec; 27 (9):1196-200
    View PubMed
  113. Shetty RK, Boilling JP, Stewart MW, Heckman MG. Differences in optical coherence tomography of the macula in advanced glaucoma and after a retinal artery occlusion. Ophthalmic Surg Lasers Imaging. 2007 Sep-Oct; 38 (5):392-8
    View PubMed
  114. Stewart MW, Brazis PW, Guier CP, Thota SH, Wilson SD. Purtscher-like retinopathy in a patient with HELLP syndrome. Am J Ophthalmol. 2007 May; 143 (5):886-7
    View PubMed
  115. Hasan SA, Stewart MW. Cystoid macular edema following photorefractive keratectomy complicated by presumptive infectious keratitis. J Cataract Refract Surg. 2007 Feb; 33(2):348-9.
    View PubMed
  116. Stewart MW. Intravitreal bevacizumab (avastin) for the treatment of chorioretinal vascular diseases. Techniques in Ophthalmology. 2007; 5(1):40-5.
  117. Stewart MW, Alvarez S, Ginsburg WW, Shetty R, McLain WC, Sleater JP. Visual recovery following Mycobacterium chelonae endophthalmitis. Ocul Immunol Inflamm. 2006 Jun; 14(3):181-3.
    View PubMed
  118. Hellinger WC, Hasan SA, Bacalis LP, Thornblom DM, Beckmann SC, Blackmore C, Forster TS, Tirey JF, Ross MJ, Nilson CD, Mamalis N, Crook JE, Bendel RE, Shetty R, Stewart MW, Bolling JP, Edelhauser HF. Outbreak of toxic anterior segment syndrome following cataract surgery associated with impurities in autoclave steam moisture. Infect Control Hosp Epidemiol. 2006 Mar; 27(3):294-8. Epub 2006 Feb 22.
    View PubMed
  119. Stewart MW, Landers MB. Transscleral intraocular lens fixation with a "homemade" needle and hook. J Cataract Refract Surg. 2006 Feb; 32(2):200-2.
    View PubMed
  120. Stewart MW, Liesegang TJ, Schwam BL. Chlamydia conjunctivitis and central retinal vein occlusion. Am J Ophthalmol. 2005 Jul; 140(1):161-2.
    View PubMed
  121. Stewart MW, Brazis PW, Barrett KM, Eidelman BH, Mendez JC. Optical coherence tomography in a case of bilateral neuroretinitis. J Neuroophthalmol. 2005 Jun; 25 (2):131-3
    View PubMed
  122. Stewart MW. Intraoperative radiographic detection of a "lost" scleral plug. Retina. 2005 Jun; 25 (4):526-7
    View PubMed
  123. Stewart MW, Bolling JP, Mendez JC. Cytomegalovirus retinitis in an immunocompetent patient. Arch Ophthalmol. 2005 Apr; 123 (4):572-4
    View PubMed
  124. Brazis PW, Stewart M, Lee AG. The uveo-meningeal syndromes. Neurologist. 2004 Jul; 10 (4):171-84
    View PubMed
  125. Stewart MW. Treatment of an avulsed retinal vessel with infrared diode laser photocoagulation. Am J Ophthalmol. 2004 Apr; 137(4):767-8.
    View PubMed
  126. Brazis PW, Lee AG, Stewart M, Capobianco D. Clinical review: The differential diagnosis of pain in the quiet eye. Neurologist. 2002; 8(2):82-100.
    View PubMed
  127. Stewart MW. Choroidal melanoma. Jacksonville Medicine. 2000; 51:393-399.
  128. Stewart MW, Lambrou FH Jr. AIDS Retinopathy. Jacksonville Medicine. 1997; 48:347-51.
  129. Stewart MW, Lambrou FH Jr, Watson M. Intravitreal ganciclovir injections for the treatment of cytomegalovirus retinitis. Ophthalmology. 1997; 104(Suppl):S149.
    View PubMed
  130. Skowsky WR, Siddiqui T, Hodgetts D, Lambrou FH, Stewart MW, Foster MT Jr. A pilot study of chronic recombinant interferon-alfa 2a for diabetic proliferative retinopathy: metabolic effects and ophthalmologic effects. J Diabetes Complications. 1996; 10(2):94-9.
    View PubMed
  131. Stewart MW. Update on CMV retinitis. Review of Ophthalmol. 1994 Nov:5-52.
  132. Pogrebniak AE, Bolling JP, Stewart MW. Argon laser-induced cataract in an infant with retinopathy of prematurity. Am J Ophthalmol. 1994 Feb 15; 117(2):261-2.
    View PubMed
  133. Friedman SM, Mames RN, Stewart MW. Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafovealar retinal telangiectasis. Ophthalmol Surg. 1993; 24:551-3.
  134. Lambrou FH, Stewart MW. Management of dislocated lens fragments during phacoemulsification. Ophthalmology. 1992 Aug; 99(8):1260-2; discussion 1268-9.
    View PubMed
  135. Hjelmeland LM, Stewart MW, Li J, Toth CA, Burns MS, Landers MB III. An experimental model of ectropion uveae and iris neovascularization in the cat. Invest Ophthalmol Vis Sci. 1992; 33(5):1796-803.
    View PubMed
  136. Stewart MW, Lambrou FH Jr. Management of dislocated lens fragments: Pars plana vitrectomy and transscleral fixation of posterior chamber lens implants. Vitreoretinal Surg and Tech. 1992; 4(3):5-6.
  137. Landers MBL III, Stewart MW, Maberely D, Serdahl C. A new inexpensive pump for vitreoretinal surgery. Arch Ophthalmol. 1991; 109:142-3.
    View PubMed
  138. Arora N, Lambrou FH Jr, Stewart MW, et al. Sudden blindness associated with central nervous symptoms in a hemodialysis patient. Nephron. 1991; 59:490-2.
    View PubMed
  139. Lambrou FH, Stewart MW. Management of dislocated lens fragments. Ophthalmol. 1991; 98(Suppl 8):169.
  140. Sternberg P Jr, Meredith TA, Stewart MW, Kaplan HJ. Retinal detachment in penetrating keratoplasty patients. Am J Ophthalmol. 1990; 109:148-52.
    View PubMed
  141. Stewart MW, Lambrou FH Jr. Lasers and retina surgery. Jacksonville Medicine. 1990; 41:448-50.
  142. Stewart MW, Gitter KA, Cohen G. Acute leukemia presenting as a unilateral exudative retinal detachment. Retina. 1989; 9:110-4.
    View PubMed
  143. Gitter KA, Stewart MW, She SC, Paulus P, Cohen G. Practical management of diabetic retinopathy. J La State Med Soc. 1988 Oct; 140(10):26-38.
    View PubMed
  144. Stewart MW, Gitter KA. Inherited retinal venous beading. Am J Ophthalmol. 1988; 106:675-81.
    View PubMed